The Karolisnka Institutet (Sweden) is ready to make History by conducting the first study involving the transplantation of stem cells into unborn babies. The treatment aims to strengthen the bone by producing collagen in infants with the brittle-bone disease Osteogenesis imperfecta in utero. The study is to be coordinated by the Karolinska Institute but to run as a collaboration between several leading European research centres and companies.
After gathering positives results in studies on mice, the Karolinska has taken a big step forward by leading the first-ever clinical trial in which unborn babies will be injected with fetal stem cells. The designed strain of stem cells targets and strengthens the bone by producing collagen. This thread-like protein found in bone and connective tissues has a similar reinforcing function to iron rods in concrete, and it is not produced in patients suffering from Osteogenesis imperfecta. The lack of collagen then produces fractures throughout the skeletal structure, leading to physical disabilities, postural abnormalities and stunted growth.
This will be the first trial,